Abstract:Objective To investigate the frequency of epidermal growth factor receptor(EGFR) mutations and their correlation with the efficacy of tyrosine kinase inhibitors (EGFR-TKI) in advanced squamous cell lung cancer.Methods This retrospective study enrolled 79 patients with advanced squamous cell lung cancer who received EGFR-TKI at Department of Thoracic Medical Oncology in Peking University Cancer Hospital from June 2004 to June 2011.Among them,67 patients had tissue and/or plasma EGFR exon 19 and 21 mutation detection in order to make an analysis on the relationship between EGFR mutation and the TKI's effect.Results The disease control rate (DCR) was 56％ in all the patients.The median progression free survival (mPFS) and median overall survival (mOS) was 3.7 months (95％ CI:2.0 -5.0) and 11.5 months (95％ CI:6.6- 14.2),respectively.Of the 67 patients who received EGFR mutation detection,there were 31 patients harboring EGFR-mutation,for whom the DCR was 71％ (22/31),and mPFS and mOS was 6.3 months (95％ CI:2.2 - 10.0) and 13.5 months (95％ CI:7.3 -18.6) respectively.36 patients' EGFR status were wild type,for whom the DCR was 44％ (16/36),mPFS and mOS was 2.2 months ( 95 ％ CI:1.1 - 4.0 ) and 6.4 months ( 95 ％ CI:4.0 - 12.0 ).There were 17 patients who received erlotinib and 7 patients who received gefitinib as second or more line treatment.mPFS and mOS were 7.9 months and 15.8 months in the erlotinib group,respectively; and the mPFS and mOS were both 6.3 months in gefitinib group; the difference between the 2 groups did not reach statistical significance.Cox-regression analysis showed that EGFR mutation was significantly correlated with PFS and OS (P ＜ 0.05,respectively).EGFR mutation was significantly correlated with DCR by Chi-square test,P ＜0.05. Conclusions EGFR mutation was a predictor for advanced squamous cell lung cancer to EGFR-TKI.However,the effect was inferior in advanced squamous cell lung cancer as compared to lung adenocarcinoma.Erlotinib tended to be superior to gefitinib.

167P: Efficacy of EGFR-TKIs for Lung Squamous Carcinomas Harboring EGFR Mutation: A Multicenter Study and Pooled Analysis of Published Reports

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports

Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Chinese Patients with Squamous Cell Carcinoma of Lung Harboring EGFR Mutation.

Efficacy of Epidermal Growth Factor Receptor (Egfr)-Tyrosine Kinase Inhibitors (tkis) in Targeted Therapy of Lung Squamous Cell Carcinoma Patients with EGFR Mutation: a Pooled Analysis.

How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation? A Bicenter Research and Pooled Analysis of Published Reports.

PUB047 Efficacy of EGFR-TKI for Lung Adenosquamous Cell Carcinoma Harboring EGFR Mutation

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis

EGFR-Mutated Squamous Cell Lung Cancer and Its Association with Outcomes.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Uncommon EGFR Mutations in a Cohort of Chinese NSCLC Patients and Outcomes of First-Line EGFR-TKIs and Platinum-Based Chemotherapy.

EGFR with TKI-sensitive Mutations in Exon 19 is Highly Expressed and Frequently Detected in Chinese Patients with Lung Squamous Carcinoma.

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Clinical Outcomes of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Recurrent Adenosquamous Carcinoma of the Lung after Resection

Egfr Mutations and the Correlation with Gefitinib Therapy in Chinese Nsclc - A Systematic Review Based on Individual Patient Data from 5 Medical Centers in China.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China

Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer

EGFR Mutations Subset in Chinese Lung Squamous Cell Carcinoma Patients

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study

Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer